Immunotherapy of urologic tumors: principles and progress

被引:8
作者
Broghammer, EL [1 ]
Ratliff, TL [1 ]
机构
[1] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
来源
UROLOGIC ONCOLOGY | 2002年 / 7卷 / 02期
关键词
immune modulation; renal cell carcinoma; prostate adenocarcinoma; transitional cell carcinoma; immunotherapeutic approaches;
D O I
10.1016/S1078-1439(01)00151-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Immunotherapy is receiving interest as an alternative or adjuvant approach to the treatment of many malignancies. The potential for immune modulation as a treatment of solid tumors is the focus of cancer researchers throughout the world. Though not a novel idea, increasing technological sophistication and continued advancement in the understanding of the immune system have increased the number of novel therapeutic approaches. In urology, BCG is an excellent example of how modulation of the immune system can be used to treat malignancy, and we are only now beginning to understand its immune mechanisms. Numerous other immunotherapeutic approaches have been and are being developed and evaluated. We provide a brief overview of immunology and its relation to tumor development and growth, and focus on some of the immunotherapeutic approaches to renal cell carcinoma, prostate adenocarcinoma, and transitional cell carcinoma of the bladder. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:45 / 56
页数:12
相关论文
共 88 条
[1]
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[2]
BELLDEGRUN A, 1993, J UROLOGY, V150, P1384, DOI 10.1016/S0022-5347(17)35785-3
[3]
Superficial bladder cancer:: The role of interferon-α [J].
Belldegrun, AS ;
Franklin, JR ;
O'Donnell, MA ;
Gomella, LG ;
Klein, E ;
Neri, R ;
Nseyo, UO ;
Ratliff, TL ;
Williams, RD .
JOURNAL OF UROLOGY, 1998, 159 (06) :1793-1801
[4]
Bercovich E, 1995, Arch Ital Urol Androl, V67, P257
[5]
ELEVATIONS OF CYTOKINES INTERLEUKIN-1, INTERLEUKIN-2 AND TUMOR-NECROSIS-FACTOR IN THE URINE OF PATIENTS AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY [J].
BOHLE, A ;
NOWC, C ;
ULMER, AJ ;
MUSEHOLD, J ;
GERDES, J ;
HOFSTETTER, AG ;
FLAD, HD .
JOURNAL OF UROLOGY, 1990, 144 (01) :59-64
[6]
Correale P, 1998, J IMMUNOL, V161, P3186
[7]
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen [J].
Correale, P ;
Walmsley, K ;
Nieroda, C ;
Zaremba, S ;
Zhu, MZ ;
Schlom, J ;
Tsang, KY .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (04) :293-300
[8]
HUMAN ANTI-MOUSE ANTIBODY-RESPONSE IN CANCER-PATIENTS FOLLOWING SINGLE LOW-DOSE INJECTIONS OF RADIOLABELED MURINE MONOCLONAL-ANTIBODIES [J].
DILLMAN, RO ;
SHAWLER, DL ;
MCCALLISTER, TJ ;
HALPERN, SE .
CANCER BIOTHERAPY, 1994, 9 (01) :17-28
[9]
Divgi CR, 1998, CLIN CANCER RES, V4, P2729
[10]
VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].
DRANOFF, G ;
JAFFEE, E ;
LAZENBY, A ;
GOLUMBEK, P ;
LEVITSKY, H ;
BROSE, K ;
JACKSON, V ;
HAMADA, H ;
PARDOLL, D ;
MULLIGAN, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543